Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15,565 Mln
Revenue (TTM)
$2,896 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
16 %
P/E Ratio
34.1
P/B Ratio
5.6
Industry P/E
65.05
EV/EBITDA
20.6
Div. Yield
0.4 %
Debt to Equity
0.1
Book Value
$37.4
EPS
$6.4
Face value
--
Shares outstanding
71,845,400
CFO
$4,090.80 Mln
EBITDA
$4,876.40 Mln
Net Profit
$3,152.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
West Pharmaceutical Services (WST)
| -33.9 | 1.9 | 0.9 | -38.4 | -10.8 | 0.2 | 14.9 |
|
BSE Sensex
| 5.2 | 7.3 | 8.4 | 12.8 | 16.0 | 21.5 | 11.7 |
|
S&P Midcap 400
| -0.9 | 12.3 | -3.4 | 1.6 | 8.3 | 14.4 | 7.3 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
West Pharmaceutical Services (WST)
| -6.9 | 49.6 | -49.8 | 65.9 | 89.0 | 54.1 | -0.1 |
|
S&P Midcap 400
| 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 | -12.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
West Pharmaceutical Services (WST)
|
216.6 | 15,564.6 | 2,895.7 | 467.2 | 19.7 | 17.2 | 34.1 | 5.6 |
| 188.3 | 13,601.8 | 3,980.8 | 409.6 | 12.2 | 10.6 | 34.1 | 3.6 | |
| 31.7 | 15,929.0 | 11,889.0 | -560.0 | -2.7 | -7.6 | -- | 2.2 | |
| 175.4 | 50,273.7 | 20,867.0 | 1,498.0 | 11.0 | 5.9 | 33.9 | 2.0 | |
| 85.5 | 33,925.1 | 4,148.0 | 535.2 | 14.2 | 25.2 | 65.1 | 14.6 | |
| 78.0 | 45,754.8 | 5,538.8 | 4,180.7 | 22.0 | 42.6 | 31.7 | 4.5 | |
| 518.1 | 40,977.4 | 3,931.8 | 895.0 | 29.5 | 58.4 | 47.2 | 27.0 | |
| 251.7 | 36,904.6 | 5,021.5 | 1,313.3 | 31.8 | 24.5 | 28.3 | 6.6 | |
| 359.5 | 21,392.3 | 2,983.3 | 657.0 | 23.5 | 36.9 | 32.7 | 10.7 | |
| 97.0 | 19,137.8 | 7,698.5 | 913.4 | 16.7 | 7.4 | 21.5 | 1.5 |
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments,... Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania. Read more
Non-Independent Chair of the Board, President & CEO
Mr. Eric M. Green
Senior VP & Chief Commercial Officer
Ms. Cindy Reiss-Clark
Headquarters
Exton, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of West Pharmaceutical Services Inc (WST) stood at $ 4,145 Mln as on 31-Mar-25
The share price of West Pharmaceutical Services Inc (WST) is $216.64 (NYSE) as of 16-May-2025 16:00 EDT. West Pharmaceutical Services Inc (WST) has given a return of -10.77% in the last 3 years.
West Pharmaceutical Services Inc (WST) has a market capitalisation of $ 15,565 Mln as on 16-May-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of West Pharmaceutical Services Inc (WST) is 5.64 times as on 16-May-2025, a 55% premium to its peers’ median range of 3.64 times.
The P/E ratio of West Pharmaceutical Services Inc (WST) is 34.06 times as on 16-May-2025, a 48% discount to its peers’ median range of 65.05 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the West Pharmaceutical Services Inc (WST) and enter the required number of quantities and click on buy to purchase the shares of West Pharmaceutical Services Inc (WST).
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
The CEO & director of Mr. Eric M. Green. is West Pharmaceutical Services Inc (WST), and CFO & Sr. VP is Ms. Cindy Reiss-Clark.
There is no promoter pledging in West Pharmaceutical Services Inc (WST).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
4,902
|
|
|
4,502
|
|
|
4,098
|
|
|
3,622
|
|
|
3,393
|
|
|
2,055
|
|
|
1,886
|
|
|
1,556
|
|
|
1,360
|
| West Pharmaceutical Services Inc. (WST) | Ratios |
|---|---|
|
Return on equity(%)
|
17.19
|
|
Operating margin(%)
|
19.67
|
|
Net Margin(%)
|
16.13
|
|
Dividend yield(%)
|
0.4
|
No, TTM profit after tax of West Pharmaceutical Services Inc (WST) was $0 Mln.
$5.96
(
